RZLT: Rezolute Inc - (NV)

RZLT新闻

• 10:06 Jefferies重申Rezolute股票买入评级，维持4美元目标价
• 10:04 Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target
• 12:08 Rezolute公司罕见疾病疗法三期临床试验结果喜忧参半
• 12:05 Rezolute shares mixed results from Phase 3 trial for rare disease therapy
• 12:08 Leerink Partners维持XOMA股票"跑赢大盘"评级，目标价45美元
• 12:07 Leerink Partners reiterates Outperform rating on XOMA stock at $45 target
• 14:47 RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
• 00:54 Rezolute首席财务官Evans购买价值$79,577的股票
• 00:54 Rezolute CFO Evans buys shares worth $79,577
• 00:54 Rezolute公司CEO Elam Nevan C.购入价值5万美元的RZLT股票
• 00:53 Elam Nevan C, Rezolute CEO, buys $50k in RZLT shares
• 00:40 Rezolute首席商务官Karnawat购入价值$19,598的股票
• 00:38 Rezolute’s CCO Karnawat buys $19,598 in shares
• 14:35 Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround
• 16:00 Micron, Nike Set To Report Earnings Next Week
• 15:12 Craig-Hallum将Rezolute股票评级下调至"持有"，因其三期临床试验失败
• 15:10 Craig-Hallum downgrades Rezolute stock to Hold on failed Phase III trial
• 14:36 尽管合作伙伴临床试验受挫，XOMA股票在Benchmark维持买入评级
• 14:35 XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback